Milind Javle, PhD, professor of Gastrointestinal Medical Oncology on the College of Texas MD Anderson Most cancers Heart, mentioned the significance of the FDA’s expedited approval course of for infigratinib within the remedy of beforehand handled regionally superior or metastatic cholangiocarcinoma.
Pharmacy Occasions interviewed Milind Javle, PhD, professor of Gastrointestinal Medical Oncology on the College of Texas MD Anderson Most cancers Heart, on the section 2 trial outcomes that led to the US FDA approval of infigratinib (Truseltiq, QED Therapeutics) for the remedy of sufferers with beforehand handled regionally superior or metastatic cholangiocarcinoma harboring an FGFR2 fusion or rearrangement.
Throughout this dialogue, Javle addressed how the US FDA’s approval of infigratinib for the remedy of beforehand handled regionally superior or metastatic cholangiocarcinoma might affect remedy choices for this affected person inhabitants and affect the sphere extra broadly.
https://www.pharmacytimes.com/view/impact-of-fda-approval-of-infigratinib-on-the-field-of-cholangiocarcinoma-treatment
